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or some time, the mechanisms that 
drive membrane traffi  cking events 
like vesicle fusion in the endocytic 
pathway were poorly understood. Slowly, 
a clearer picture has started to emerge, 
thanks to the work of people like Harald 
Stenmark (1–5).
As a child, Stenmark says he loved 
taking long treks on cross-country skis, 
leaving his mark across snowy fi  elds. As 
an adult, he still loves to ski, but he’s 
leaving most of his marks in a different 
fi  eld: from his lab at the University of 
Oslo, Norway, Stenmark has blazed new 
trails, exploring the function of FYVE-
fi  nger domain–containing proteins (2,3), 
which bind to the membrane lipid phos-
phatidylinositol 3-phosphate (PI3P). His 
work has helped uncover the essential 
role of FYVE-fi  nger proteins and PI3P in 
vesicular fusion (4, 5) and other mem-
brane traffi  cking events (6). We called 
him to talk about how he hit his stride in 
his research.
DIAGONAL STRIDE
Have you lived most of 
your life in Norway?
Yes, I grew up in a couple 
of small fi  shing villages in 
northern Norway, where 
the winters are quite long 
but the skiing is good. My 
parents were teachers, but 
my fi   rst exposure to sci-
ence was through an excel-
lent high school teacher named Bjørn 
Reppen. He was very interested in the 
natural sciences and mathematics, and 
he got me interested, too.
I wasn’t sure what I wanted to study 
when I reached university, but I was ad-
vised that I could fi  nd a good career in 
pharmaceutical research, so I pursued 
that. At the end of my studies, I heard a 
seminar by Sjur Olsnes about immuno-
toxins, which are conjugates of protein 
toxins and antibodies, and their ability to 
selectively kill cancer cells. I was in-
trigued and asked to join his lab at the 
Norwegian Radium Hospital in Oslo for 
my PhD.
My fi  rst project with Olsnes was to 
identify the receptor for diphtheria toxin, 
which at that point was not known. I tried 
different strategies to identify this recep-
tor, and they were all unsuccessful. I 
think I worked on this for two years be-
fore realizing that it was not going any-
where. Finally, a new postdoc, Stephen 
McGill, joined the lab. He had expertise 
in molecular biology, and he taught me 
how to make plasmid constructs. We 
made some mutants of diphtheria toxin 
to try to fi  nd out which part of the toxin 
binds to the receptor and which part is 
required for its translocation across the 
membrane. This project was what fi  nally 
gave me my PhD. I identifi  ed the region 
within the so-called B-fragment of diph-
theria toxin that mediates its receptor 
binding and membrane translocation, and 
I also showed that a non-toxic mutant of 
diphtheria toxin can be used to shuttle 
proteins into cells.
Was your postdoctoral 
work a large departure 
from your graduate work?
Not really. I had visited the 
EMBL at Heidelberg dur-
ing my PhD and was very 
impressed with the place. I 
decided I wanted to do my 
postdoctoral work there, 
and a postdoc in Sjur’s lab 
suggested Marino Zerial, who was just 
setting up his lab there. Marino was work-
ing on Rab GTPases, which I thought was 
quite an interesting subject. Since Rabs 
are involved in membrane traffi  cking, it 
was related to some of the work I had 
done with diphtheria toxin, and I could 
learn new skills in molecular biology and 
cloning there, as well.
When I joined his lab, Marino was 
excited about functional studies of Rab5, 
which he had found was targeted to early 
endosomes. And again, my fi  rst project 
was to identify a receptor: we wanted to 
fi  nd what proteins recruit Rab5 to early 
endosomes. So again, I tried different ap-
proaches to identify a receptor for Rab5, 
and again I failed. I’m really not good at 
receptor identifi  cation! [laughs] But in 
parallel, as a kind of side project, I mu-
tated Rab5 to make versions locked in 
either their GDP- or GTP-bound form to 
investigate the importance of the GTPase 
cycle for Rab5 function. And with the 
GTP-bound form we got these giant en-
dosomes in the cell—it was really strik-
ing. That got us thinking that Rab5-GTP 
might recruit proteins that mediate vesi-
cle fusion, and then of course we went 
looking for proteins that could bind to 
Rab5-GTP.
What did you ﬁ  nd?
Using a yeast two-hybrid screen, we 
pulled out a protein that we called Rabap-
tin5, which we then showed was required 
for Rab5-dependent homotypic fusion of 
endosomes in vitro. I must say, I was a 
little bit naïve at that point—I thought that 
now that we had identifi  ed the effector of 
Rab5, it would be quite easy to understand 
how Rab5 works in endosome fusion. Of 
course, as we know now, that was far from 
the truth, because I think Marino alone 
has identified something like 30 Rab5-
binding proteins.
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Stenmark studies how FYVE-finger proteins control cellular membrane dynamics.
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TIP-TURN
Where did that leave you?
Well, then I returned to Oslo for a short-
term research associate position at Nor-
wegian Radium Hospital. Toward the 
end of my time in Marino’s lab, I had 
been working with an immunopatholo-
gist, Ban-Hock Toh from Melbourne, to 
characterize a protein his group had 
cloned called early endosomal antigen-1 
(EEA1). This protein was a more spe-
cifi  c marker for early endosomes than 
even Rab5. I decided to focus my efforts 
on EEA1 rather than to continue to work 
on Rab5, in part because I got some good 
advice from Marino that at this point in 
my career it would be im-
portant to develop my own 
research interests.
So the fi  rst thing we did 
in my lab was to chop EEA1 
into pieces and see what 
part binds to endosomes, 
and by this we found that it 
was the C-terminal part that bound to en-
dosomes. This region contains a zinc-fi  nger 
motif that is found in many other proteins. 
We named it a FYVE-fi  nger domain, after 
the zinc-fi  nger and the initial letters of the 
fi  rst four proteins in which we found this 
conserved region. It’s now been found in 
more than 30 human proteins.
How does the FYVE-ﬁ  nger domain 
mediate protein binding to endosomes?
At fi  rst we really didn’t understand this. 
We tried to do a screen to fi  nd endosomal 
proteins that bind EEA1, and we didn’t 
succeed. But later, Silvia Corvera’s lab 
showed that EEA1 binding to endosomes 
was disrupted by the PI3-kinase inhibitor 
wortmannin, and we realized that we 
should be looking for a lipid, not a pro-
tein. EEA1’s FYVE-fi  nger domain binds 
to the lipid PI3P, which we later found to 
be enriched on endosomes. We also real-
ized that the EEA1 FYVE-fi  nger domain 
alone was not suffi  cient for binding en-
dosomes; there’s another region up-
stream of the FYVE-fi   nger that’s also 
required…  and that turned out to be a 
Rab5 binding domain! That was a bit 
ironic, of course, because 
my idea was to stay away 
from Rab5-interacting pro-
teins, and the fi  rst protein I 
started studying turned out 
to bind Rab5.
We’ve also studied other 
FYVE-fi  nger proteins. One 
of these, Hrs, is a protein that helps in 
sorting of ubiquitinated growth factor 
receptors to the lysosome.
FREE SKATE
Are FYVE-ﬁ  nger proteins still a major 
focus of your lab?
We’re still working on characterizing 
other FYVE-finger proteins. But one 
thing I am very excited about right now 
is that we’re going in an unexpected di-
rection: cell division. Several years ago 
we developed a probe for 
PI3P called 2xFYVE, 
which is composed of 
two tandem FYVE-fi  nger 
domains. When we used 
it in live cells, in addition 
to the endosomal stain-
ing that we observed in 
our fi  rst studies, we also 
saw this striking, consist-
ent staining of a structure 
in between two dividing 
cells. This turned out to 
be the mid-body, the stuff 
that you have between 
two daughter cells during 
late cytokinesis.
We then asked if formation of PI3P is 
important for cell division, and, indeed, 
when we knocked down subunits of the 
class III PI3 kinase complex that forms 
PI3P, we could arrest cells in cytokine-
sis. So now we’re excited to investigate 
the involvement of membrane traffi  cking 
in cell division, not only during cytoki-
nesis but also at earlier stages. That’s a 
fi  eld that has not been studied that much 
so far.
What’s your philosophical approach to 
your work?
My philosophy of science is that it should 
be fun. If it’s not fun, then it’s not worth 
doing, because it’s a lot of hard work, 
and success in science takes persistence. 
I started out being quite unsuccessful, 
but I didn’t lose my enthusiasm. I feel 
that it’s a little bit of a hobby, not simply 
an occupation.
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Harald and his wife Yan hiked off-piste at Svalbard, in Norway, 
for a nice view.
PI3P on endosomes is visualized with Sten-
mark’s 2xFYVE construct (red). Microtubules 
are shown in green.
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“If [science is] 
not fun, then 
it’s not worth 
doing.”